10 patents currently held
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Feb 2027. from the record
Of the 5 now held by other companies, 4 name Sanofi Mature IP as their current owner, and 1 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
9
Ending by 2030
Feb 2027
Next term end
9
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 2 of the currently held patents qualify as notable.
Notable
Ends Jan 2029 · High confidence
Also notable
Ends Feb 2027 · High confidence
Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same
US 8,378,128
The largest patent family in this portfolio, 6 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors
US 7,935,819
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027.
Formerly held, still cited
Notable
Ends Oct 2030 · High confidence
A family of 8 related applications built on the 2020 grant. Protection runs to 2030.
now held by Sanofi Mature IP
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Oct 12, 2027The maintenance fee for Crystalline Form of Cabazitaxel and Process for Preparing the Same (US 9,309,210) comes due Oct 12, 2027. Unpaid by Apr 12, 2028, it lapses early.
Recent changes
- 2 terms have ended since Aug 17, 2026
What they patent
The 5 largest of its 9 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,935,819 | Novel Cyclic Urea Derivatives, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors In force · High confidence | In force | High confidence | |
| US 7,674,795 | Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof In force · High confidence | In force | High confidence | |
| US 8,058,290 | 7-Substituted Aza-Indazoles, Compositions Containing Same, Production Method and Use Thereof In force · High confidence | In force | High confidence | |
| US 8,008,322 | Substituted Pyrazolopyridines, Compositions Containing Them, Method for the Production Thereof, and Their Use In force · High confidence | In force | High confidence | |
| US 8,034,939 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities In force · High confidence | In force | High confidence | |
| US 8,378,128 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same In force · High confidence | In force | High confidence | |
| US 10,160,739 | Crystalline Forms of Dimethoxy Docetaxel and Methods for Preparing the Same In force · High confidence | In force | High confidence | |
| US 8,163,768 | 1,4-Dihydropyridine-FUSED Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them In force · High confidence | In force | High confidence | |
| US 8,481,589 | Novel Taxoid-Based Compositions In force · High confidence | In force | High confidence | |
| US 9,309,210 | Crystalline Form of Cabazitaxel and Process for Preparing the Same In force · High confidence | In force | High confidence |
Also on record, not counted in the 10: 5 patents in force now held by others · 215 patents ended · 151 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
17 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed